2021-11-16-世界卫生组织-Cervical_cancer_Germany_2021_country_profile_1页_64kb

German Cervical Cancer Profile Summary

Based on the provided report, here is a concise analysis and summary of Germany's cervical cancer data as of December 2021. The summary focuses on key indicators such as incidence, mortality, prevention strategies (primary and secondary vaccination and screening), treatment availability, and preventive measures.

Morbidity and Mortality

• Cervical cancer incidence in 2020 was high enough that an age-standardized rate of 7.6 per 100,000 women was reported. The cumulative risk by age 74 was 0.7%.
• In 2019, cervical cancer deaths reached 2,100, with a mortality-to-incidence ratio of 0.44 in 2020. A population-based cancer registry was confirmed to exist.

Primary Prevention

• HPV vaccination coverage among girls in 2020 was 43% for the final dose, with the program introduced in 2007 at age 15. Vaccination against HPV is included nationally, targeting girls aged 9-14 years.
• Risk factors included low tobacco use prevalence among women aged 15+ (0.01%), but HIV incidence data was not fully specified. The program coverage was 58% of the target population by age 15.

Secondary Prevention (Screening)

• A national cervical cancer screening program exists, using cytology as the primary test for women over 30, with HPV testing recommended from age 35. Target age ranges from 20 to 65 years, and approximately 89% of women were screened in the last 5 years, with 93% ever screened.

Treatment and Supportive Care

• National guidelines on cervical cancer management are accessible, and healthcare services include radiotherapy and brachytherapy units available per 10,000 cancer patients. There is a cancer center at tertiary level, along with specialists such as radiation oncologists and pathologists.
• Palliative care is generally available for patients with non-communicable diseases. Additional data shows high availability of opioid consumption in healthcare settings.

WHO Elimination Strategy (2030 Targets)

• Reference is made to the WHO strategy, with ongoing efforts to achieve elimination, including high vaccination and screening rates in Germany as of 2021.